Tonix Pharmaceuticals Holding Corp.

What they do

Tonix commercializes TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults, plus Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) for acute migraine in adults in the U.S. It runs a commercial platform spanning sales, marketing, market access, distribution, and patient support. It is also developing a pipeline of CNS, infectious disease, immunology, and rare disease candidates, including TNX-102 SL for major depressive disorder and acute stress disorder, TNX-4800 for Lyme disease prevention, TNX-1500 for transplant rejection and autoimmune disease, and TNX-1300 for cocaine intoxication.

Revenue drivers

• TONMYA — FDA-approved in August 2025 and launched November 17, 2025 for fibromyalgia in adults; Q2 2026 net sales totaled approximately $11 million, up 197% quarter-over-quarter, and comprised the bulk of Q2 2026 revenue of $13.5 million.
• Migraine products (Zembrace SymTouch and Tosymra) — Two FDA-approved sumatriptan products for acute migraine in adults in the U.S., marketed through the same commercial platform; their individual contribution is not separately quantified in the excerpts.
• Total reported revenue — Annual revenue rose from $7.8 million in 2023 to $10.1 million in 2024 and $13.1 million in 2025; quarterly revenue accelerated from $3.3 million in Q3 2025 to $6.9 million in Q1 2026 and $13.5 million in Q2 2026.

Recent performance

Second quarter 2026 revenue was $13.5 million, with TONMYA net sales of approximately $11 million, up 197% quarter-over-quarter. Total prescriptions were 12,592, up 100% quarter-over-quarter, with new patient prescriptions up 36% and refills up 207%; bridge prescriptions through the digital pharmacy channel are included in total prescriptions but do not immediately generate net product revenue. Payer coverage reached approximately 136 million covered lives, about 43% of the U.S. total. The company reported cash and cash equivalents of approximately $176.2 million as of June 30, 2026. Full-year 2025 net loss was $124.0 million on revenue of $13.1 million, and operating cash flow has been negative in every year presented ($99.8 million used in 2025).

Strategy

Tonix is prioritizing TONMYA's launch, including expanding payer coverage across commercial, managed Medicare, and Medicaid channels and broadening prescriber reach. It expects to deploy 50 new sales representatives by September 2026, bringing the sales force to approximately 150 people. Pipeline priorities include the Phase 2 HORIZON study of TNX-102 SL in major depressive disorder, which enrolled its first patient, and a Phase 2 adaptive field study of TNX-4800 for Lyme disease prevention targeted to start in the first quarter of 2027 pending final FDA review and agreement on the protocol. Other programs include TNX-102 SL for acute stress disorder under an investigator-initiated IND at the University of North Carolina, TNX-1500 for kidney transplant rejection and autoimmune disease, and TNX-1300 for cocaine intoxication.

Risks

• Continued operating losses and cash use — Tonix has reported annual net losses from $92.3 million in 2021 to $124.0 million in 2025 and negative operating cash flow in every year presented, requiring ongoing capital.
• Dependence on a single new product — TONMYA, launched November 17, 2025, is the company's first internally developed approved product and generated approximately $11 million of Q2 2026 net sales, making the launch's trajectory central to results.
• Payer coverage and reimbursement — Approximately 136 million covered lives represent about 43% of U.S. lives, and the company states bridge prescriptions provided through its digital pharmacy channel while coverage determinations are pending do not immediately generate net product revenue.
• Clinical and regulatory timing — Pipeline programs remain subject to FDA clearance and protocol agreement, including the TNX-4800 Phase 2 field study in Lyme disease prevention targeted for the first quarter of 2027 and the MGH investigator-initiated TNX-1500 study pending FDA clearance of the IND.

Outlook

Management states it expects to deploy 50 additional sales representatives by September 2026, bringing the sales force to approximately 150 people, and to reach total coverage of roughly 145 million lives (about 46% of U.S. covered lives) when a managed Medicare agreement takes effect January 1, 2027. It expects the TNX-4800 Phase 2 adaptive field study in Lyme disease prevention to start enrollment in the first quarter of 2027 after alignment with FDA. It also expects to meet with FDA in 2026 regarding TNX-1300 and to report topline OASIS data for TNX-102 SL in acute stress disorder mid-2027. The HORIZON Phase 2 study of TNX-102 SL in major depressive disorder has begun enrolling.